These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 21523727)

  • 21. Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns.
    Guan W; Zhou L; Li Y; Yang E; Liu Y; Lv N; Fu L; Ding Y; Wang N; Fang N; Liu Q; Wang B; Li F; Zhang J; Wang M; Wang L; Jing Y; Li Y; Yu L
    Exp Hematol Oncol; 2021 Apr; 10(1):27. PubMed ID: 33836835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FLT3-ITD and CD135 Over-Expression are Frequent Findings of Poor Survival in Adult Patients with Acute Leukemias.
    Vela-Ojeda J; Cardenas PV; Garcia-Ruiz Esparza MA; Montiel Cervantes LA; Chavez JG; Caballero AH; Majluf-Cruz A; Vega-López A; Reyes-Maldonado E
    Arch Med Res; 2021 Feb; 52(2):217-223. PubMed ID: 33109387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [FLT3 and NPM1 gene mutations in patients with acute myeloid leukemias and the impact of FLT3-ITD mutations on the survival of patients with a normal karyotype].
    Martynkevich IS; Gritsaev SV; Moskalenko MV; Ivanova MP; Aksenova VIu; Tiranova SA; Abdulkadyrov KM
    Ter Arkh; 2010; 82(12):33-9. PubMed ID: 21516736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [FMS-like tyrosine kinase 3 gene mutations in acute myeloid leukemia].
    Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1135-9. PubMed ID: 19840437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FLT3-ITD Mutations in Egyptian Patients of Acute Myeloid Leukemia: Correlation with Cytogenetic, FAB Subgroups and Prognosis.
    Adnan-Awad S; Gaber O; Eltokhy SA; Mourad D; Amer M; Kandeel EZ; Eldesouky I
    Clin Lab; 2017 May; 63(5):1027-1034. PubMed ID: 28627830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
    Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
    Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fms-like tyrosine kinase 3 mutations in childhood acute leukemias and their association with prognosis.
    Karabacak BH; Erbey F; Bayram I; Yilmaz S; Acipayam C; Kilinç Y; Tanyeli A
    Asian Pac J Cancer Prev; 2010; 11(4):923-7. PubMed ID: 21133602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
    Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
    Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FLT3 internal tandem duplication and FLT3-D835 mutation in 80 AML patients categorized into cytogenetic risk groups.
    Mały E; Przyborsk M; Nowak T; Nowak J; Januszkiewicz D
    Postepy Hig Med Dosw (Online); 2010 Oct; 64():466-70. PubMed ID: 20966504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in
    Sharawat SK; Raina V; Kumar L; Sharma A; Bakhshi R; Vishnubhatla S; Gupta R; Bakhshi S
    Indian J Med Res; 2016 May; 143(Supplement):S11-S16. PubMed ID: 27748272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NUP98::NSD1 and FLT3/ITD co-expression is an independent predictor of poor prognosis in pediatric AML patients.
    Wang JW; Yu-Li ; Yang XG; Xu LH
    BMC Pediatr; 2024 Aug; 24(1):547. PubMed ID: 39182032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population.
    Suzuki R; Onizuka M; Kojima M; Shimada M; Okamura K; Fukagawa S; Tsuboi K; Kikuchi A; Kobayashi H; Shintani A; Ogawa Y; Kawada H; Hotta T; Ando K
    Int J Hematol; 2007 Dec; 86(5):422-8. PubMed ID: 18192111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML.
    Li W; Zhang L; Huang L; Mi Y; Wang J
    Leuk Res; 2012 Feb; 36(2):186-91. PubMed ID: 21907407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [FLT3 mutations in children with acute myeloid leukemia: a single center study].
    Ruan M; Wang YQ; Zhang L; Liu TF; Liu F; Liu XM; Zhang JY; Zou Y; Chen YM; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Nov; 13(11):863-6. PubMed ID: 22099191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation.
    Jiang A; Jiang H; Brandwein J; Kamel-Reid S; Chang H
    Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
    Kottaridis PD; Gale RE; Frew ME; Harrison G; Langabeer SE; Belton AA; Walker H; Wheatley K; Bowen DT; Burnett AK; Goldstone AH; Linch DC
    Blood; 2001 Sep; 98(6):1752-9. PubMed ID: 11535508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical Characteristics and Prognostic Relevance of Co-Mutated Genes in Acute Myeloid Leukemia Patients with
    Chen Y; Xie YY; Fang Y; Hong M; Liu WJ; Zhou X; Zhang W; Shi JN; Qian SX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1032-1038. PubMed ID: 39192394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.